Edgestream Partners L.P. acquired a new position in Stryker Corporation (NYSE:SYK – Free Report) during the third quarter, Holdings Channel.com reports. The firm acquired 27,069 shares of the medical technology company’s stock, valued at approximately $7,455,000.
Several other institutional investors have also recently made changes to their positions in the business. International Assets Investment Management LLC boosted its stake in Stryker by 1,432.8% during the 3rd quarter. International Assets Investment Management LLC now owns 25,000 shares of the medical technology company’s stock worth $6,885,000 after purchasing an additional 23,369 shares during the last quarter. Amundi raised its holdings in shares of Stryker by 18.3% during the 2nd quarter. Amundi now owns 1,246,353 shares of the medical technology company’s stock worth $392,402,000 after acquiring an additional 192,447 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Stryker by 8.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 859,544 shares of the medical technology company’s stock valued at $270,642,000 after acquiring an additional 65,333 shares during the last quarter. Veritas Asset Management LLP acquired a new position in shares of Stryker during the 2nd quarter valued at about $168,057,000. Finally, Bank of America Corp DE purchased a new stake in shares of Stryker in the second quarter valued at about $1,404,284,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.
Stryker Stock Performance
Shares of SYK stock opened at $317.20 on Wednesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 2.18. The firm has a market cap of $120.76 billion, a P/E ratio of 33.78, a P/E/G ratio of 2.13 and a beta of 0.78. The firm’s 50 day moving average price is $293.26 and its 200-day moving average price is $322.17. Stryker Corporation has a one year low of $267.00 and a one year high of $389.33.
Stryker (NYSE:SYK – Get Free Report) last announced its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). Stryker had a net margin of 13.78% and a return on equity of 23.74%. The firm had revenue of $6.52 billion during the quarter, compared to analysts’ expectations of $6.62 billion. During the same period in the previous year, the firm earned $3.19 EPS. The firm’s revenue for the quarter was up 7.6% compared to the same quarter last year. As a group, equities research analysts predict that Stryker Corporation will post 14.85 EPS for the current year.
Analysts Set New Price Targets
Several research firms have recently commented on SYK. TD Cowen reduced their price target on shares of Stryker from $298.00 to $290.00 and set a “hold” rating on the stock in a research report on Friday, October 30th. BTIG Research lowered their price objective on Stryker from $316.00 to $304.00 and set a “buy” rating for the company in a research report on Friday, October 30th. Rothschild & Co Redburn cut their target price on Stryker from $360.00 to $336.00 in a research note on Monday, November 2nd. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Stryker in a research note on Wednesday, October 7th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $323.00 price target (down from $370.00) on shares of Stryker in a research note on Friday, October 30th. Twenty-one analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $342.19.
Check Out Our Latest Analysis on SYK
Insider Buying and Selling at Stryker
In other news, Director Ronda Stryker sold 550,000 shares of Stryker stock in a transaction on Friday, November 6th. The stock was sold at an average price of $325.32, for a total value of $178,926,000.00. Following the completion of the sale, the director directly owned 1,701,375 shares of the company’s stock, valued at approximately $553,491,315. The trade was a 24.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the sale, the insider owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 4.60% of the company’s stock.
Stryker Company Profile
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
Featured Stories
- Five stocks we like better than Stryker
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
